Business Summary

Imugene Limited is an Australia-based clinical-stage immuno-oncology company. The Company is engaged in developing a range of new immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies, such as CAR T’s for solid tumors. Its PD-1 B-cell immunotherapy (PD1-Vaxx), aims to induce the body to produce polyclonal antibodies that block PD-1 signaling, and thus produce an anticancer effect. Its HER-Vaxx is a B-cell activating cancer immunotherapy designed to treat tumors that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. Its clinical trial candidates include VAXINIA (CF33 + hNIS), CHECKvacc (CF33 + hNIS + PD-L1), B-Vaxx and others.